Search

Your search keyword '"Viswanathan, Akila N."' showing total 792 results
Start Over Author "Viswanathan, Akila N."
792 results on '"Viswanathan, Akila N."'

155. Brachytherapy: An overview for clinicians

Author

Chargari, Cyrus, primary, Deutsch, Eric, additional, Blanchard, Pierre, additional, Gouy, Sebastien, additional, Martelli, Hélène, additional, Guérin, Florent, additional, Dumas, Isabelle, additional, Bossi, Alberto, additional, Morice, Philippe, additional, Viswanathan, Akila N., additional, and Haie‐Meder, Christine, additional

Published
2019
Full Text
View/download PDF

157. Management of Nodal Disease in Advanced Cervical Cancer

Author

Jürgenliemk-Schulz, Ina-Maria, primary, Beriwal, Sushil, additional, de Leeuw, Astrid A.C., additional, Lindegaard, Jacob Christian, additional, Nomden, Christel Nadine, additional, Pötter, Richard, additional, Tanderup, Kari, additional, Viswanathan, Akila N., additional, and Erickson, Beth, additional

Published
2019
Full Text
View/download PDF

158. Association of a Simulated Institutional Gender Equity Initiative With Gender-Based Disparities in Medical School Faculty Salaries and Promotions

Author

Rao, Avani D., primary, Nicholas, Sarah E., additional, Kachniarz, Bartlomiej, additional, Hu, Chen, additional, Redmond, Kristin J., additional, Deville, Curtiland, additional, Wright, Jean L., additional, Page, Brandi R., additional, Terezakis, Stephanie, additional, Viswanathan, Akila N., additional, DeWeese, Theodore L., additional, Fivush, Barbara A., additional, and Alcorn, Sara R., additional

Published
2018
Full Text
View/download PDF

159. A novel minimally invasive dynamic‐shield, intensity‐modulated brachytherapy system for the treatment of cervical cancer.

Author

Morcos, Marc, Antaki, Majd, Viswanathan, Akila N., and Enger, Shirin A.

Subjects
MONTE Carlo method, RADIOISOTOPE brachytherapy, CERVICAL cancer, CANCER treatment, INTERSTITIAL brachytherapy, RADIOISOTOPES, RECTUM
Abstract

Purpose: To present a novel, MRI‐compatible dynamicshield intensity modulated brachytherapy (IMBT) applicator and delivery system using 192Ir, 75Se, and 169Yb radioisotopes for the treatment of locally advanced cervical cancer. Needle‐free IMBT is a promising technique for improving target coverage and organs at risk (OAR) sparing. Methods and materials: The IMBT delivery system dynamically controls the rotation of a novel tungsten shield placed inside an MRI‐compatible, 6‐mm wide intrauterine tandem. Using 36 cervical cancer cases, conventional intracavitary brachytherapy (IC‐BT) and intracavitary/interstitial brachytherapy (IC/IS‐BT) (10Ci 192Ir) plans were compared to IMBT (10Ci 192Ir; 11.5Ci 75Se; 44Ci 169Yb). All plans were generated using the Geant4‐based Monte Carlo dose calculation engine, RapidBrachyMC. Treatment plans were optimized then normalized to the same high‐risk clinical target volume (HR‐CTV) D90 and the D2cc for bladder, rectum, and sigmoid in the research brachytherapy planning system, RapidBrachyMCTPS. Plans were renormalized until either of the three OAR reached dose limits to calculate the maximum achievable HR‐CTV D90 and D98. Results: Compared to IC‐BT, IMBT with either of the three radionuclides significantly improves the HR‐CTV D90 and D98 by up to 5.2% ± 0.3% (P < 0.001) and 6.7% ± 0.5% (P < 0.001), respectively, with the largest dosimetric enhancement when using 169Yb followed by 75Se and then 192Ir. Similarly, D2cc for all OAR improved with IMBT by up to 7.7% ± 0.6% (P < 0.001). For IC/IS‐BT cases, needle‐free IMBT achieved clinically acceptable plans with 169Yb‐based IMBT further improving HR‐CTV D98 by 1.5% ± 0.2% (P = 0.034) and decreasing sigmoid D2cc by 1.9% ± 0.4% (P = 0.048). Delivery times for IMBT are increased by a factor of 1.7, 3.3, and 2.3 for 192Ir, 75Se, and 169Yb, respectively, relative to conventional 192Ir BT. Conclusions: Dynamic shield IMBT provides a promising alternative to conventional IC‐ and IC/IS‐BT techniques with significant dosimetric enhancements and even greater improvements with intermediate energy radionuclides. The ability to deliver a highly conformal, OAR‐sparing dose without IS needles provides a simplified method for improving the therapeutic ratio less invasively and in a less resource intensive manner. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

161. Assessing radiation oncology research needs in India: Results of a physician survey.

Author

Bhatia, Rohini Kishor, (Chopra), Supriya Sastri, Reddy Palkonda, Vijay Anand, Giri, G. V., Senapati, Surendranath, Bilimagga, Ramesh S., Chadha, Manjeet, Viswanathan, Akila N., Grover, Surbhi, Sastri Chopra, Supriya, and Palkonda, Vijay Anand Reddy

Subjects
ONCOLOGISTS, PHYSICIANS, RADIATION, ONCOLOGY, TRAINING needs
Abstract

Background: In India, where the annual incidence of cancer is projected to reach 1.7 million by 2020, the need for clinical research to establish the most effective, resource-guided, and evidence-based care is paramount. In this study, we sought to better understand the research training needs of radiation oncologists in India.Methods: A 12 item questionnaire was developed to assess research training needs and was distributed at the research methods course jointly organized by Indian College of Radiation Oncology, the American Brachytherapy Society, and Education Committee of the American Society of Therapeutic Radiation Oncology during the Indian Cancer Congress, 2017.Results: Of 100 participants who received the questionnaire, 63% responded. Ninety percent (56/63) were Radiation Oncologists. Forty-two percent (26/63) of respondents had previously conducted research. A longer length of practice (>10 years) was significantly associated with conducting research (odds ratio (OR) 6.99, P = 0.031) and having formal research training trended toward significance (OR 3.03, P = 0.058). The most common reason for not conducting research was "lack of training" (41%, 14/34). The most common types of research conducted were Audits and Retrospective studies (62%, 16/26), followed by a Phase I/II/III Trial (46%, 10/26). Having formal research training was a significant factor associated with writing a protocol (OR 5.53, P = 0.016). Limited training in research methods (54%, 13/24) and lack of mentorship (42%, 10/24) were cited as reasons for not developing a protocol. Ninety-seven percent (57/59) of respondents were interested in a didactic session on research, specifically focusing on biostatistics.Conclusions: With research training and mentorship, there is a greater likelihood that concepts and written protocols will translate into successfully completed studies in radiation therapy. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

164. CHARACTERIZING GRADIENT ECHO SIGNAL DECAYS IN GYNECOLOGIC CANCERS AT 3T USING A GAUSSIAN AUGMENTATION OF THE MONO-EXPONENTIAL (GAME) MODEL

Author

Ciris, Pelin A., Balasubramanian, Mukund, Damato, Antonio L., Seethamraju, Ravi T., Tempany-Afdhal, Clare M., Mulkern, Robert V., and Viswanathan, Akila N.

Subjects
Adult, Models, Statistical, Genital Neoplasms, Female, Normal Distribution, Reproducibility of Results, Middle Aged, Image Enhancement, Magnetic Resonance Imaging, Sensitivity and Specificity, Article, Oxygen, Image Interpretation, Computer-Assisted, Biomarkers, Tumor, Humans, Tumor Hypoxia, Computer Simulation, Female, Aged
Abstract

To assess whether R2* mapping with a standard Monoexponential (ME) or a Gaussian Augmentation of the Monoexponential (GAME) decay model better characterizes gradient-echo signal decays in gynecological cancers after external beam radiation therapy at 3T, and evaluate implications of modeling for noninvasive identification of intratumoral hypoxia.Multi-gradient-echo signals were acquired on 25 consecutive patients with gynecologic cancers and three healthy participants during inhalation of different oxygen concentrations at 3T. Data were fitted with both ME and GAME models. Models were compared using F-tests in tumors and muscles in patients, muscles, cervix, and uterus in healthy participants, and across oxygenation levels.GAME significantly improved fitting over ME (P0.05): Improvements with GAME covered 34% of tumor regions-of-interest on average, ranging from 6% (of a vaginal tumor) to 68% (of a cervical tumor) in individual tumors. Improvements with GAME were more prominent in areas that would be assumed hypoxic based on ME alone, reaching 90% as ME R2* approached 100 Hz. Gradient echo decay parameters at different oxygenation levels were not significantly different (P = 0.81).R2* may prove sensitive to hypoxia; however, inaccurate representations of underlying data may limit the success of quantitative assessments. Although the degree to which R2 or σ values correlate with hypoxia remains unknown, improved characterization with GAME increases the potential for determining any correlates of fit parameters with biomarkers, such as oxygenation status. J. MAGN. RESON. IMAGING 2016;44:1020-1030.

Published
2016

165. Medical Student Perspectives on a Multi-institutional Clerkship Curriculum: A Report From the Radiation Oncology Education Collaborative Study Group

Author

Ye, Jason C., Mohindra, Pranshu, Spektor, Alexander, Krishnan, Monica S., Chmura, Steven J., Howard, Andrew R., Viswanathan, Akila N., MacDonald, Shannon M., Thaker, Nikhil G., Das, Prajnan, Mancini, Brandon R., Higgins, Susan A., Braunstein, Steve, Haas-Kogan, Daphne, Bradley, Kristin A., Hung, Arthur Y., Thomas, Charles R., Jr., Kharofa, Jordan, Wheatley, Matt, Currey, Adam, Parashar, Bhupesh, Du, Kevin, Jimenez, Rachel B., and Golden, Daniel W.

Published
2015
Full Text
View/download PDF

166. Pelvic Radiation and Normal Tissue Toxicity

Author

Nicholas, Sarah, primary, Chen, Linda, additional, Choflet, Amanda, additional, Fader, Amanda, additional, Guss, Zachary, additional, Hazell, Sarah, additional, Song, Daniel Y., additional, Tran, Phuoc T., additional, and Viswanathan, Akila N., additional

Published
2017
Full Text
View/download PDF

167. Corrigendum to “comparison of outcomes for MR-guided versus CT-guided high-dose-rate interstitial brachytherapy in women with locally advanced carcinoma of the cervix” [Gynecol. Oncol. 145 (2017) 284–290]

Author

Kamran, Sophia C., primary, Manuel, Matthias M., additional, Cho, Linda P., additional, Damato, Antonio L., additional, Schmidt, Ehud J., additional, Tempany, Clare, additional, Cormack, Robert A., additional, and Viswanathan, Akila N., additional

Published
2017
Full Text
View/download PDF

168. Cervical cancer: A global health crisis

Author

Small, William, primary, Bacon, Monica A., additional, Bajaj, Amishi, additional, Chuang, Linus T., additional, Fisher, Brandon J., additional, Harkenrider, Matthew M., additional, Jhingran, Anuja, additional, Kitchener, Henry C., additional, Mileshkin, Linda R., additional, Viswanathan, Akila N., additional, and Gaffney, David K., additional

Published
2017
Full Text
View/download PDF

169. Radiation Oncology in India: Challenges and Opportunities

Author

Grover, Surbhi, primary, Gudi, Shivakumar, additional, Gandhi, Ajeet Kumar, additional, Puri, Priya M., additional, Olson, Adam C., additional, Rodin, Danielle, additional, Balogun, Onyi, additional, Dhillon, Preet K., additional, Sharma, Daya Nand, additional, Rath, Goura Kishor, additional, Shrivastava, Shyam Kishore, additional, Viswanathan, Akila N., additional, and Mahantshetty, Umesh, additional

Published
2017
Full Text
View/download PDF

170. Characterization of efficacy and toxicity after high-dose pelvic reirradiation with palliative intent for genitourinary second malignant neoplasms or local recurrences after full-dose radiation therapy in the pelvis: A high-volume cancer center experience

Author

Kamran, Sophia C., primary, Harshman, Lauren C., additional, Bhagwat, Mandar S., additional, Muralidhar, Vinayak, additional, Nguyen, Paul L., additional, Martin, Neil E., additional, La Follette, Stephanie, additional, Faso, Sarah, additional, Viswanathan, Akila N., additional, Efstathiou, Jason A., additional, and Beard, Clair J., additional

Published
2017
Full Text
View/download PDF

171. HIV Infection and Survival Among Women With Cervical Cancer

Author

Dryden-Peterson, Scott, primary, Bvochora-Nsingo, Memory, additional, Suneja, Gita, additional, Efstathiou, Jason A., additional, Grover, Surbhi, additional, Chiyapo, Sebathu, additional, Ramogola-Masire, Doreen, additional, Kebabonye-Pusoentsi, Malebogo, additional, Clayman, Rebecca, additional, Mapes, Abigail C., additional, Tapela, Neo, additional, Asmelash, Aida, additional, Medhin, Heluf, additional, Viswanathan, Akila N., additional, Russell, Anthony H., additional, Lin, Lilie L., additional, Kayembe, Mukendi K.A., additional, Mmalane, Mompati, additional, Randall, Thomas C., additional, Chabner, Bruce, additional, and Lockman, Shahin, additional

Published
2016
Full Text
View/download PDF

172. NRG ONCOLOGY/RTOG 0921: A PHASE II STUDY OF POSTOPERATIVE INTENSITY MODULATED RADIATION THERAPY (IMRT) WITH CONCURRENT CISPLATIN AND BEVACIZUMAB FOLLOWED BY CARBOPLATIN AND PACLITAXEL FOR PATIENTS WITH ENDOMETRIAL CANCER

Author

Viswanathan, Akila N., Moughan, Jennifer, Miller, Brigitte E., Xiao, Ying, Jhingran, Anuja, Portelance, Lorraine, Bosch, Walter, Matulonis, Ursula, Horowitz, Neil, Mannel, Robert S., Souhami, Luis, Erickson, Beth, Winter, Kathryn, Small, William, and Gaffney, David

Subjects
Adult, Aged, 80 and over, Paclitaxel, Chemoradiotherapy, Adjuvant, Middle Aged, Hysterectomy, Article, Disease-Free Survival, Endometrial Neoplasms, Bevacizumab, Antineoplastic Combined Chemotherapy Protocols, Humans, Lymph Node Excision, Female, Postoperative Period, Radiotherapy, Intensity-Modulated, Cisplatin, Aged
Abstract

The current study was conducted to assess acute and late adverse events (AEs), overall survival (OS), pelvic failure, regional failure, distant failure, and disease-free survival in a prospective phase 2 clinical trial of bevacizumab and pelvic intensity-modulated radiotherapy (IMRT) with chemotherapy in patients with high-risk endometrial cancer.Patients underwent a hysterectomy and lymph node removal, and had ≥1 of the following high-risk factors: grade 3 carcinoma with50% myometrial invasion, grade 2 or 3 disease with any cervical stromal invasion, or known extrauterine extension confined to the pelvis. Treatment included pelvic IMRT and concurrent cisplatin on days 1 and 29 of radiation and bevacizumab (at a dose of 5 mg/kg on days 1, 15, and 29 of radiation) followed by adjuvant carboplatin and paclitaxel for 4 cycles. The primary endpoint was grade ≥3 AEs occurring within the first 90 days (toxicity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events [version 4.0]).A total of 34 patients were accrued from November 2009 through December 2011, 30 of whom were eligible and received study treatment. Seven of 30 patients (23.3%; 1-sided 95% confidence interval, 10.6%-36.0%) developed grade ≥3 treatment-related nonhematologic toxicities within 90 days; an additional 6 patients experienced grade ≥3 toxicities between 90 and 365 days after treatment. The 2-year OS rate was 96.7% and the disease-free survival rate was 79.1%. No patient developed a within-field pelvic failure and no patients with International Federation of Gynecology and Obstetrics stage I to IIIA disease developed disease recurrence after a median follow-up of 26 months.Postoperative bevacizumab added to chemotherapy and pelvic IMRT appears to be well tolerated and results in high OS rates at 2 years for patients with high-risk endometrial carcinoma.

Published
2015

173. Treatment completion and tolerability of women with cervical cancer with and without HIV in Botswana.

Author

Grover, Surbhi, primary, Bvochora-Nsingo, Memory Fadziso, additional, MacDuffie, Emily, additional, Ratcliffe, Sarah, additional, Wileyto, E. Paul, additional, Bhatia, Rohini, additional, Yeager, Alyssa, additional, Chiyapo, Sebathu Phillip, additional, Gaolebale, Ponatshego A, additional, Russell, Anthony Henry, additional, Makufa, Remigio, additional, Karunmekayi, Talkmore, additional, Balang, Dawn, additional, Kayembe, Mukendi, additional, Ramogola-Masire, Doreen, additional, Dryden-Peterson, Scott, additional, Viswanathan, Akila N., additional, Robertson, Erle, additional, Zetola, Nicola Mario, additional, and Lin, Lilie L., additional

Published
2016
Full Text
View/download PDF

181. Multi-Institutional Implementation and Evaluation of a Curriculum for the Medical Student Clerkship in Radiation Oncology

Author

Golden, Daniel W., primary, Braunstein, Steve, additional, Jimenez, Rachel B., additional, Mohindra, Pranshu, additional, Spektor, Alexander, additional, Ye, Jason C., additional, Bradley, Kristin A., additional, Chmura, Steven J., additional, Currey, Adam, additional, Das, Prajnan, additional, Du, Kevin, additional, Haas-Kogan, Daphne, additional, Howard, Andrew R., additional, Higgins, Susan A., additional, Hung, Arthur Y., additional, Kharofa, Jordan, additional, Krishnan, Monica S., additional, MacDonald, Shannon M., additional, Mancini, Brandon R., additional, Parashar, Bhupesh, additional, Thaker, Nikhil G., additional, Thomas, Charles R., additional, Viswanathan, Akila N., additional, and Wheatley, Matt, additional

Published
2016
Full Text
View/download PDF

185. Colaboradores

Author

Anscher, Mitchell S., Boggs, D. Hunter, Chan, Michael D., Cramer, Christina K., Cuaron, John, Santos, Jennifer De Los, Galloway, Thomas J., Garsa, Adam A., Gottschalk, Alexander R., Hess, Clayton B., Jeans, Elizabeth B., Kaidar-Person, Orit, Kalman, Noah S., Kamran, Sophia C., Kirkpatrick, John P., Krishnan, Monica, Marks, Lawrence B., Rossi, Peter J., Shiloh, Ron, Smith, Sophia K., Spector, Denise, Urdaneta, Alfredo I., Viswanathan, Akila N., Wu, Abraham, Yock, Torunn I., Yom, Sue S., Zagar, Timothy M., and Zhao, Sherry

Published
2018
Full Text
View/download PDF

186. Validation of mathematical models for the prediction of organs-at-risk dosimetric metrics in high-dose-rate gynecologic interstitial brachytherapy

Author

Damato, Antonio L., Viswanathan, Akila N., and Cormack, Robert A.

Subjects
Radiation Therapy Physics, Organs at Risk, Genital Neoplasms, Female, Radiotherapy Planning, Computer-Assisted, Brachytherapy, Humans, Female, Radiotherapy Dosage, Models, Theoretical, Radiation Dosage, Radiometry
Abstract

PURPOSE: Given the complicated nature of an interstitial gynecologic brachytherapy treatment plan, the use of a quantitative tool to evaluate the quality of the achieved metrics compared to clinical practice would be advantageous. For this purpose, predictive mathematical models to predict the D(2cc) of rectum and bladder in interstitial gynecologic brachytherapy are discussed and validated. METHODS: Previous plans were used to establish the relationship between D2cc and the overlapping volume of the organ at risk with the targeted area (C0) or a 1-cm expansion of the target area (C1). Three mathematical models were evaluated: D(2cc) = α*C(1) + β (LIN); D(2cc) = α – exp(–β*C(0)) (EXP); and a mixed approach (MIX), where both C(0) and C(1) were inputs of the model. The parameters of the models were optimized on a training set of patient data, and the predictive error of each model (predicted D(2cc) − real D(2cc)) was calculated on a validation set of patient data. The data of 20 patients were used to perform a K-fold cross validation analysis, with K = 2, 4, 6, 8, 10, and 20. RESULTS: MIX was associated with the smallest mean prediction error

Published
2013

187. The American Brachytherapy Society Treatment Recommendations for Locally Advanced Carcinoma of the Cervix Part II: High Dose-Rate Brachytherapy

Author

Viswanathan, Akila N., Beriwal, Sushil, De Los Santos, Jennifer, Demanes, D. Jeffrey, Gaffney, David, Hansen, Jorgen, Jones, Ellen, Kirisits, Christian, Thomadsen, Bruce, and Erickson, Beth

Subjects
Brachytherapy, Practice Guidelines as Topic, Humans, Uterine Cervical Neoplasms, Female, Radiotherapy Dosage, Article, United States
Abstract

This report presents an update to the American Brachytherapy Society (ABS) high-dose-rate (HDR) brachytherapy guidelines for locally advanced cervical cancer.Members of the ABS with expertise in cervical cancer formulated updated guidelines for HDR brachytherapy using tandem and ring, ovoids, cylinder, or interstitial applicators for locally advanced cervical cancer. These guidelines were written based on medical evidence in the literature and input of clinical experts in gynecologic brachytherapy.The ABS affirms the essential curative role of tandem-based brachytherapy in the management of locally advanced cervical cancer. Proper applicator selection, insertion, and imaging are fundamental aspects of the procedure. Three-dimensional imaging with magnetic resonance or computed tomography or radiographic imaging may be used for treatment planning. Dosimetry must be performed after each insertion before treatment delivery. Applicator placement, dose specification, and dose fractionation must be documented, quality assurance measures must be performed, and followup information must be obtained. A variety of dose/fractionation schedules and methods for integrating brachytherapy with external-beam radiation exist. The recommended tumor dose in 2-Gray (Gy) per fraction radiobiologic equivalence (normalized therapy dose) is 80-90Gy, depending on tumor size at the time of brachytherapy. Dose limits for normal tissues are discussed.These guidelines update those of 2000 and provide a comprehensive description of HDR cervical cancer brachytherapy in 2011.

Published
2012
Full Text
View/download PDF

189. Dosimetric Comparison of HDR Treatments of the Cervix Using Unshielded and Shielded Intracavitary Brachytherapy Applicators - A Preliminary Investigation

Author

Buzurovic, Ivan, primary, Damato, Antonio L., additional, Cormack, Robert A., additional, O'Farrell, Desmond, additional, Bhagwat, Mandar S., additional, Friesen, Scott, additional, Hansen, Jorgen, additional, Lee, Larissa J., additional, Devlin, Phillip M., additional, and Viswanathan, Akila N., additional

Published
2015
Full Text
View/download PDF

190. Is the Systematic Contouring of the Bowel in Image-Based Cervical-Cancer HDR Brachytherapy Necessary?

Author

Damato, Antonio L., primary, Bhagwat, Mandar S., additional, Buzurovic, Ivan, additional, Cormack, Robert A., additional, Friesen, Scott, additional, Hansen, Jorgen, additional, Lee, Larissa J., additional, O'Farrell, Desmond, additional, Williams, Christopher L., additional, Devlin, Phillip M., additional, and Viswanathan, Akila N., additional

Published
2015
Full Text
View/download PDF

191. Does plastic surgical consultation improve the outcome of patients undergoing radical vulvectomy for squamous cell carcinoma of the vulva?

Author

Aviki, Emeline M., primary, Esselen, Katharine M., additional, Barcia, Sara M., additional, Nucci, Marisa R., additional, Horowitz, Neil S., additional, Feltmate, Colleen M., additional, Berkowitz, Ross S., additional, Orgill, Dennis G., additional, Viswanathan, Akila N., additional, and Muto, Michael G., additional

Published
2015
Full Text
View/download PDF

192. Brachytherapy: Where Has It Gone?

Author

Petereit, Daniel G., primary, Frank, Steven J., additional, Viswanathan, Akila N., additional, Erickson, Beth, additional, Eifel, Patricia, additional, Nguyen, Paul L., additional, and Wazer, David E., additional

Published
2015
Full Text
View/download PDF

196. Gynecologic Cancer InterGroup (GCIG) consensus review for small cell carcinoma of the cervix.

Author

Satoh, Toyomi, Takei, Yuji, Treilleux, Isabelle, Devouassoux-Shisheboran, Mojgan, Ledermann, Jonathan, Viswanathan, Akila N, Mahner, Sven, Provencher, Diane M, Mileshkin, Linda, Åvall-Lundqvist, Elisabeth, Pautier, Patricia, Reed, Nicholas Simon, Fujiwara, Keiichi, Satoh, Toyomi, Takei, Yuji, Treilleux, Isabelle, Devouassoux-Shisheboran, Mojgan, Ledermann, Jonathan, Viswanathan, Akila N, Mahner, Sven, Provencher, Diane M, Mileshkin, Linda, Åvall-Lundqvist, Elisabeth, Pautier, Patricia, Reed, Nicholas Simon, and Fujiwara, Keiichi

Abstract

Small cell carcinoma of the cervix (SCCC) is a rare histological entity of uterine cervical cancer. Compared with other common histological types, squamous cell carcinoma or adenocarcinoma, the outcome of SCCC is poor because of the high incidence of nodal or distant metastasis even with early stage. In this review, current consensus of epidemiology, pathology, and initial treatment for SCCC will be discussed.

Published
2014
Full Text
View/download PDF

197. Independent brachytherapy plan verification software: Improving efficacy and efficiency

Author

Damato, Antonio L., primary, Devlin, Phillip M., additional, Bhagwat, Mandar S., additional, Buzurovic, Ivan, additional, Friesen, Scott, additional, Hansen, Jorgen L., additional, Lee, Larissa J., additional, Molodowitch, Christina, additional, Nguyen, Paul L., additional, O’Farrell, Desmond A., additional, Viswanathan, Akila N., additional, Williams, Christopher L., additional, Killoran, Joseph H., additional, and Cormack, Robert A., additional

Published
2014
Full Text
View/download PDF

198. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Uterine Corpus and Cervix

Author

Hasegawa, Kosei, primary, Nagao, Shoji, additional, Yasuda, Masanori, additional, Millan, David, additional, Viswanathan, Akila N., additional, Glasspool, Rosalind M., additional, Devouassoux-Shisheboran, Mojgan, additional, Covens, Alan, additional, Lorusso, Domenica, additional, Kurzeder, Christian, additional, Kim, Jae-Weon, additional, Gladieff, Laurence, additional, Bryce, Jane, additional, Friedlander, Michael, additional, and Fujiwara, Keiichi, additional

Published
2014
Full Text
View/download PDF

200. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Small Cell Carcinoma of the Cervix

Author

Satoh, Toyomi, primary, Takei, Yuji, additional, Treilleux, Isabelle, additional, Devouassoux-Shisheboran, Mojgan, additional, Ledermann, Jonathan, additional, Viswanathan, Akila N., additional, Mahner, Sven, additional, Provencher, Diane M., additional, Mileshkin, Linda, additional, Åvall-Lundqvist, Elizabeth, additional, Pautier, Patricia, additional, Reed, Nicholas Simon, additional, and Fujiwara, Keiichi, additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results